Loureirin A, derived from Dragon's blood, promoted drug delivery and efficacy in pancreatic cancer via vascular promotion
Authors:
- Jing WangJWJing Wang
- Xinchen LiuXLXinchen Liu
- Xiusong TangXTXiusong Tang
- Songyan GaoSGSongyan Gao
- Shudong ZhangSZShudong Zhang
- Yan WeiYWYan Wei
- Hongbo LiHLHongbo Li
- 19 August 2026
- journal article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 834
Abstract
No abstract availableFunding Information
- Natural Science Foundation of Shanghai Municipality (23ZR1463300)
- Natural Science Foundation of Fujian Province (2025J02032)
This publication has 43 references indexed in Scilit:
- Liposomal Irinotecan: A Review as First-Line Therapy in Metastatic Pancreatic AdenocarcinomaDrugs, 2025
- A mechanistic insight into the anticancer potentials of resveratrol: Current perspectivesPhytotherapy Research, 2024
- Enzyme‐Activated Prodrug‐Based Smart Liposomes Specifically Enhance Tumor Hemoperfusion with Efficient Drug Delivery to Pancreatic Cancer Cells and Stellate CellsAdvanced Functional Materials, 2021
- MT1‐MMP‐Activated Liposomes to Improve Tumor Blood Perfusion and Drug Delivery for Enhanced Pancreatic Cancer TherapyAdvanced Science, 2020
- Hematopoietic growth factors and tumor angiogenesisCancer Letters, 2019
- Pharmacological and physical vessel modulation strategies to improve EPR-mediated drug targeting to tumorsAdvanced Drug Delivery Reviews, 2017
- Dual-Action Combination Therapy Enhances Angiogenesis while Reducing Tumor Growth and SpreadCancer Cell, 2015
- Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced SurvivalCancer Cell, 2014
- Endothelial-pericyte interactions in angiogenesisCell and tissue research, 2003
- Inhibition of angiogenesis at endothelial cell levelMicroscopy Research and Technique, 2002